Abbott Laboratories
ABT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000001800
In the last 90 days, Abbott Laboratories insiders filed 0 open-market purchases and 3 sales; 3,000 institutions reported holding it in 13F filings for Q2 2026, worth $125.2B in total; 3 superinvestors hold it, including Southeastern Asset Management (Longleaf) and Soros Fund Management.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:02 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 22, 2026 | Jan 22, 2025 | Jan 24, 2024 | Jan 25, 2023 | Jan 26, 2022 |
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| Cost of revenue | $19.3B | $18.7B | $18.0B | $19.1B | $18.5B |
| Research and development | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B |
| Selling, general and administrative | $12.3B | $11.7B | $10.9B | $11.2B | $11.3B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| Interest expense | – | – | $637.0M | $558.0M | $533.0M |
| Income tax | $1.94B | -$6.39B | $941.0M | $1.37B | $1.14B |
| Net income | $6.52B | $13.4B | $5.72B | $6.93B | $7.07B |
| EPS, basic | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 |
| EPS, diluted | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Weighted shares, basic | 1.74B | 1.74B | 1.74B | 1.75B | 1.77B |
| Weighted shares, diluted | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B |
| Margins and growth | |||||
| Operating margin | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% |
| Revenue growth, year over year | +5.7% | +4.6% | −8.1% | +1.3% | +24.5% |
| Net income growth, year over year | −51.3% | +134.2% | −17.5% | −2.0% | +57.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 22, 2026 | Jan 22, 2025 | Jan 24, 2024 | Jan 25, 2023 | Jan 26, 2022 |
| Cash and equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B |
| Short-term investments | $417.0M | $351.0M | $383.0M | $288.0M | $450.0M |
| Accounts receivable | $7.93B | $6.92B | $6.57B | $6.22B | $6.49B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B |
| Total current assets | $26.0B | $23.7B | $22.7B | $25.2B | $24.2B |
| Property, plant and equipment | $11.8B | $10.7B | $10.2B | $9.16B | $8.96B |
| Goodwill | $24.0B | $23.1B | $23.7B | $22.8B | $23.2B |
| Intangible assets | $5.53B | $6.65B | $8.81B | $10.5B | $12.7B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B |
| Short-term debt | $3.03B | $1.50B | $1.08B | $2.25B | $0 |
| Total current liabilities | $16.5B | $14.2B | $13.8B | $15.5B | $13.1B |
| Long-term debt | $9.90B | $12.6B | $13.6B | $14.5B | $17.3B |
| Shareholders' equity | $52.8B | $47.9B | $38.8B | $36.9B | $36.0B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 22, 2026 | Jan 22, 2025 | Jan 24, 2024 | Jan 25, 2023 | Jan 26, 2022 |
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.5B |
| Capital expenditures | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B |
| Stock-based compensation | $664.0M | $673.0M | $644.0M | $685.0M | $640.0M |
| Dividends paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B |
| Share buybacks | $893.0M | $1.29B | $1.23B | $3.79B | $2.30B |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -$2.01B |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -$5.49B |
| Net change in cash | $906.0M | $720.0M | -$2.99B | $83.0M | $2.96B |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.5% | 1.6% | 1.6% | 1.6% | 1.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 30, 2026 | 1.73B | −0.4% | SEC |
| Jun 30, 2026 | 1.73B | −0.6% | SEC |
| Mar 31, 2026 | 1.74B | +0.1% | SEC |
| Jan 31, 2026 | 1.74B | +0.2% | SEC |
| Sep 30, 2025 | 1.74B | +0.3% | SEC |
| Jun 30, 2025 | 1.74B | 0.0% | SEC |
| Mar 31, 2025 | 1.74B | 0.0% | SEC |
| Jan 31, 2025 | 1.73B | 0.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.